A Rare Case of Paraneoplastic Minimal Change Disease in Neuroendocrine Cancer (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1280; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He was started on palliative chemotherapy with capecitabine and temozolomide in January 2026, along with zoledronate for osseous metastases...Renal function continues to worsen, and immunosuppressive therapy is being considered while Oncology evaluates treatment with lanreotide and 177Lu-Dotatate...Additional studies are needed to better define the roles of immunosuppressive versus oncologic treatment. Kidney biopsy remains essential for diagnosis, exclusion of alternative renal lesions, and therapeutic decision-making."
Clinical • Acute Kidney Injury • Endocrine Cancer • Glomerulonephritis • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Nephrology • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • SSTR
|
|
Roshni Radhakrishna; Jordan R. Evans; Mark A. Teruel; Lihong Bu
|